Senescent-cell vaccine

A senescent-cell vaccine is an immunological strategy aimed at training the adaptive immune system to recognize and eliminate senescent cells in vivo, analogous to anti-tumour vaccination. The approach was demonstrated preclinically by Suda and colleagues (2021, Nature Aging): mice vaccinated with peptides derived from glycoprotein nonmetastatic melanoma protein B (GPNMB), a surface antigen overexpressed on senescent cells, developed GPNMB-specific cytotoxic T-lymphocyte responses that reduced senescent cell burden, improved physical function, and partially replicated healthspan benefits seen with pharmacological senolytics in progeroid (Ercc1-mutant accelerated-aging) and diet-induced obese mouse models. The concept is in early discovery phase: GPNMB is not exclusively expressed on senescent cells, potential immune tolerance and autoimmunity risks have not been evaluated in humans, no clinical trial has been initiated, and whether a single antigen target can cover the heterogeneous senescent cell landscape across tissues remains unresolved. This is a preclinical proof-of-concept, not an available or approaching clinical product.